Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema
Phase 3
- Conditions
- Diabetic Macular Edema
- Registration Number
- NCT00370669
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)
- Detailed Description
we entered 150 eyes into the study that recruitment of cases finished recently.Eligible eyes randomly assign to one of the study arms including intravitreal bevacizumzb, intravitreal bevacizumzb/triamcinolone and macular photocoagulation groups. Every patient needs at least 1 year followup. During this time BCVA, OCT, FA will be done for each patient and inaccording to interpretation of datas and fundus exam repeatation of injection will be done.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- case with clear media IOP below 23 mm/Hg female after menopause at least for 12 months or had 2 contraceptive roots visual acuity between 20/50 to 20/320
Exclusion Criteria
- no PRP or N.d YAG laser in past 6 months no intraocular surgery in past 12 months
- CVA in past 12 months blood sugar above 250
- active infection in extraocular adnexa
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method visual acuity central macular thickness
- Secondary Outcome Measures
Name Time Method Leakage in fluorescein angiography intraocular pressure cataract progression anterior chamber reaction
Trial Locations
- Locations (1)
Masoud Soheilian
🇮🇷Tehran, Iran, Islamic Republic of